TGTX
HEALTHCARETG Therapeutics Inc
AI Insight
What's Moving TGTX Today?
No stock-specific AI insight has been generated for TGTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$25.28$57.38
$53.94
Fundamentals
Market Cap$8.3B
P/E Ratio19.0
EPS$2.86
Dividend Yield—
Dividend / Share—
ROE112.6%
Profit Margin65.9%
Debt / Equity—
Trading
Volume3.1M
Avg Volume (10D)—
Shares Outstanding153.1M
TGTX News
22 articles- Is TG Therapeutics, Inc. (TGTX) A Good Stock To Buy Now?Yahoo Finance·Jun 19, 2026
- Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?Yahoo Finance·Jun 19, 2026
- TG Therapeutics Stock Is On A Hot Streak: Why It's Up 79% And ClimbingYahoo Finance·Jun 18, 2026
- TGTX Stock Continues Rally For 8 Straight Sessions On New BRIUMVI Clinical DataStocktwits·Jun 17, 2026
- Dow Jones Futures Signal Market Bounce, But Then What? Oracle Dives, SpaceX IPO On Launch PadYahoo Finance·Jun 11, 2026
- TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?Yahoo Finance·Jun 11, 2026
- Why This IBD Stock Of The Day, A Roche Rival, Just Broke Out To A Five-Year HighYahoo Finance·Jun 10, 2026
- Why TG Therapeutics (TGTX) Is Up 18.4% After Advancing At‑Home Subcutaneous BRIUMVI In MS TreatmentYahoo Finance·Jun 10, 2026
- TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MGYahoo Finance·Jun 10, 2026
- Dow Jones Futures Tumble As Trump Says Iran Will 'Have To Pay The Price'; CPI Inflation On TapYahoo Finance·Jun 10, 2026
- TGTX Stock Jumps 5% On Positive Early Data For At-Home BRIUMVI In Muscle DiseaseStocktwits·Jun 9, 2026
- Sector Update: Healthcare Stocks Rise Pre-Bell TuesdayYahoo Finance·Jun 9, 2026
- TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 TrialYahoo Finance·Jun 9, 2026
- A Look At TG Therapeutics (TGTX) Valuation After Recent Positive BRIUMVI Trial UpdatesYahoo Finance·Jun 9, 2026
- Why Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?Yahoo Finance·Jun 5, 2026
- TGTX Stock Up on Positive Phase I Data for Subcutaneous BriumviYahoo Finance·Jun 4, 2026
- Dow Jones Futures Rise, But Broadcom, CrowdStrike, Ciena Hit Techs; SpaceX IPO Price Target SetYahoo Finance·Jun 4, 2026
- TG Therapeutics Flashes An Early Buy Signal — What Drove The Bullish JumpYahoo Finance·Jun 3, 2026
- Sector Update: Healthcare Stocks Higher Late AfternoonYahoo Finance·Jun 3, 2026
- TGTX Stock Applies Brakes On 5-Session Losing Streak – Retail Eyes ‘Multi-Billion’ Sales As At-Home Multiple Sclerosis Treatment Gets BoostStocktwits·Jun 3, 2026
- Evaluating TG Therapeutics (TGTX) Valuation After Recent Share Price Pullback And BRIUMVI Growth StorySimply Wall Street·Jun 3, 2026
- TG Therapeutics (TGTX) Q1 2026 Results Put 66% Net Margin Narrative To The TestSimply Wall Street·May 7, 2026
All 22 articles loaded
Price Data
Open$54.00
Previous Close$54.40
Day High$55.52
Day Low$52.70
52 Week High$57.38
52 Week Low$25.28
52-Week Range
$25.28$57.38
$53.94
Fundamentals
Market Cap$8.3B
P/E Ratio19.0
EPS$2.86
Dividend Yield—
Dividend / Share—
ROE112.6%
Profit Margin65.9%
Debt / Equity—
Trading
Volume3.1M
Avg Volume (10D)—
Shares Outstanding153.1M
About TG Therapeutics Inc
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—